For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative | 5,981 | |||
| Research and development | 5,423 | |||
| Total operating expenses | 11,404 | |||
| Loss from operations | -11,404 | |||
| Gain on investment | 22 | |||
| Interest expense | 194 | |||
| Interest expense - related party | 83 | |||
| Loss on extinguishment of debt | -825 | |||
| Loss on extinguishment of debt - related party | 333 | |||
| Net change in fair value of digital assets | -62 | |||
| Net change in fair value of trading marketable securities | 0 | |||
| Total other (expense) income | -1,475 | |||
| Provision for income taxes | 0 | |||
| Net loss | -12,879 | |||
| Foreign currency translation adjustments | -70 | |||
| Total other comprehensive income (loss) | -70 | |||
| Total comprehensive loss | -12,949 | |||
| Diluted EPS | -12.52 | |||
| Diluted Average Shares | 1,029,000 | |||
ARTELO BIOSCIENCES, INC. (ARTL)
ARTELO BIOSCIENCES, INC. (ARTL)